scholarly journals Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells

2018 ◽  
Vol 9 (1) ◽  
Author(s):  
Maria C. Naskou ◽  
Scarlett M. Sumner ◽  
Anna Chocallo ◽  
Hannah Kemelmakher ◽  
Merrilee Thoresen ◽  
...  
Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S111 ◽  
Author(s):  
S.H. Mei ◽  
M. Salkhordeh ◽  
F. Xue ◽  
J. Zhang ◽  
I. Watpool ◽  
...  

2013 ◽  
Vol 95 (2) ◽  
pp. 693-698 ◽  
Author(s):  
Jong-pil Seo ◽  
Nao Tsuzuki ◽  
Shingo Haneda ◽  
Kazutaka Yamada ◽  
Hidefumi Furuoka ◽  
...  

2021 ◽  
Vol 234 ◽  
pp. 110203
Author(s):  
Shannon S. Connard ◽  
Renata L. Linardi ◽  
Kayla M. Even ◽  
Alix K. Berglund ◽  
Lauren V. Schnabel ◽  
...  

2015 ◽  
Vol 26 (3) ◽  
pp. 73-80 ◽  
Author(s):  
Takafumi SASAO ◽  
Yuki FUKUDA ◽  
Sayako YOSHIDA ◽  
Shihori MIYABARA ◽  
Yoshinori KASASHIMA ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-21 ◽  
Author(s):  
Sunghoon Jung ◽  
Krishna M. Panchalingam ◽  
Lawrence Rosenberg ◽  
Leo A. Behie

Human mesenchymal stem cells (hMSCs) are presently being evaluated for their therapeutic potential in clinical studies to treat various diseases, disorders, and injuries. To date, early-phase studies have indicated that the use of both autologous and allogeneic hMSCs appear to be safe; however, efficacy has not been demonstrated in recent late-stage clinical trials. Optimized cell bioprocessing protocols may enhance the efficacy as well as safety of hMSC therapeutics. Classical media used for generating hMSCs are typically supplemented with ill-defined supplements such as fetal bovine serum (FBS) or human-sourced alternatives. Ideally, culture media are desired to have well-defined serum-free formulations that support the efficient production of hMSCs while maintaining their therapeutic and differentiation capacity. Towards this objective, we review here current cell culture media for hMSCs and discuss medium development strategies.


Sign in / Sign up

Export Citation Format

Share Document